Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine

This 5-year follow-up of the double-blinded, placebo-controlled phase 3 DEN-03-IB trial evaluating the efficacy and safety of the Butantan dengue vaccine in participants aged 2–59 years in Brazil found that a single dose of the vaccine was effective against DENV-1 and DENV-2, regardless of serostatus at baseline, and was safe.